Merck & Co Inc Acquisition of Prometheus Biosciences- M&A Call Transcript

Apr 17, 2023 / 12:00PM GMT

Thank you for standing by. Welcome to the Merck & Company Investor Event announcing the acquisition of Prometheus Biosciences, Inc. (Operator Instructions). This call is being recorded. If you have any objections, you may disconnect at this time.

I would now like to turn the call over to Mr. Peter Dannenbaum, Vice President, Investor Relations. Sir, you may begin.

Peter Dannenbaum - Merck & Co., Inc. - VP of IR

Thank you, Michelle. Good morning, everyone. Welcome to Merck's investor call highlighting the announced acquisition of Prometheus Biosciences. Our agenda this morning includes Rob Davis, Merck's Chairman and Chief Executive Officer, who will lead off our presentation. Rob will be followed by Dr. Dean Li, President of Merck Research Labs; Dr. Eliav Barr, our Chief Medical Officer and Head of Global Clinical Development; Chirfi Guindo, Chief Marketing Officer of Human Health; and Caroline Litchfield, Chief Financial Officer. Q&A will follow.

Before we get started, we would like to remind you that some of the statements that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot